Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Buyse, Mark"'
Autor:
Holmes, Frankie Ann, Moy, Beverly, Delaloge, Suzette, Chia, Stephen, Ejlertsen, Bent, Mansi, Janine, Iwata, Hiroji, Gnant, Michael, Buyse, Mark, Barrios, Carlos, Silovski, Tajana, Separovic, Robert, Bashford, Anna, Guerrero-Zotano, Angel, Denduluri, Neelima, Patt, Debra, Gokmen, Erhan, Gore, Ira, Smith, John, Bryce, Richard, Xu, Feng, Wong, Alvin, Martin, Miguel, Chan, Arlene
Neratinib (NERLYNX®) is an irreversible pan-HER inhibitor that significantly improves invasive disease-free survival (iDFS) compared with placebo when given as extended adjuvant therapy in patients with HER2-positive (HER2+) early breast cancer afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::2179206eed72e1ffb8baee306d480140
https://www.bib.irb.hr/1274392
https://www.bib.irb.hr/1274392
Autor:
Chakravartty, Arunava1 (AUTHOR) arunava.chakravartty@novartis.com
Publikováno v:
Journal of Biopharmaceutical Statistics. 2016, Vol. 26 Issue 1, p189-190. 2p.
Autor:
Farmer, Kathy kathyfarmer@mindspring.com
Publikováno v:
Flutist Quarterly. Summer2016, Vol. 41 Issue 4, p45-48. 4p.
Autor:
Oza, A. M.1 amit.oza@uhn.on.ca, Castonguay, V.1, Tsoref, D.1, Diaz-Padilla, I.1, Karakasis, K.1, Mackay, H.1, Welch, S.2, Weberpals, J.3, Hoskins, P.4, Plante, M.5, Provencher, D.6, Tonkin, K.7, Covens, A.8, Ghatage, P.9, Gregoire, J.10, Hirte, H.11, Miller, D.4, Rosen, B.1, Maroun, J.3, Buyse, M.11
Publikováno v:
Current Oncology. Oct2011 Supplement, Vol. 18, pS20-S27. 8p. 2 Charts.
Publikováno v:
Proceedings of the ACM SIGPLAN 1992 Conference: Programming Language Design & Implementation; Jun1992, p1-11, 11p
Publikováno v:
JAMA Oncology; May2018, Vol. 4 Issue 5, pe180204-1, 1p